Published in
Elsevier, European Journal of Cancer, (148), p. 24-35, 2021
DOI: 10.1016/j.ejca.2021.02.005
Links
Tools
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study
Journal article published in 2021 by
Alessio Cortellini 
,
Katia Cannita,
Marcello Tiseo ,
Diego L. Cortinovis ,
Joachim G. J. V. Aerts,
Cinzia Baldessari ,
Raffaele Giusti ,
Miriam G. Ferrara ,
Ettore D'Argento,
Francesco Grossi,
Annalisa Guida,
Rossana Berardi,
Alessandro Morabito ,
Carlo Genova,
Lorenzo Antonuzzo
and other authors.
,
Katia Cannita,
Marcello Tiseo ,
Diego L. Cortinovis ,
Joachim G. J. V. Aerts,
Cinzia Baldessari ,
Raffaele Giusti ,
Miriam G. Ferrara ,
Ettore D'Argento,
Francesco Grossi,
Annalisa Guida,
Rossana Berardi,
Alessandro Morabito ,
Carlo Genova,
Lorenzo Antonuzzo
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 